Rizzo Manfredi, Kotur-Stevuljevic Jelena, Berneis Kaspar, Spinas Giatgen, Rini Giovam Battista, Jelic-Ivanovic Zorana, Spasojevic-Kalimanovska Vesna, Vekic Jelena
Department of Internal Medicine and Emerging Diseases, University of Palermo, Italy.
Transl Res. 2009 May;153(5):217-23. doi: 10.1016/j.trsl.2009.01.008. Epub 2009 Feb 23.
Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required to explore the potential synergistic impact of markers of oxidative stress and atherogenic dyslipidemia, particularly small dense LDL, on cardiovascular risk.
尽管体外研究和临床试验的结果表明氧化应激与心血管风险之间存在密切关联，但迄今为止，仍没有令人信服的数据表明抗氧化剂治疗可能会减少血管事件。低密度脂蛋白（LDL）的氧化修饰是动脉粥样硬化的早期阶段，与较大、浮力更强的颗粒相比，小而致密的LDL更容易被氧化。氧化型LDL是亚临床和临床动脉粥样硬化的独立预测指标。最近的研究表明，新的治疗策略可能会考虑从循环中清除此类颗粒。需要进一步的研究来探讨氧化应激标志物和致动脉粥样硬化性血脂异常，特别是小而致密的LDL，对心血管风险的潜在协同影响。
